Gubra ApS
Industry
- Biotechnology
- Large Molecule
- Drug Discovery Technologies
- Contract Research Organization-CRO
- In Vitro Diagnostics
- Chemistry, Immunoassay
- Pharmaceuticals
Latest on Gubra ApS
Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AiPharma Joins Effort To Develop Fujifi
Although family-owned Boehringer Ingelheim GmbH is the only private firm in the top 20 largest biopharmas, its executives are quick to explain that most of their operations function in the same way
Clearly happy with their collaboration to date, German drug company Boehringer Ingelheim GmbH has inked a third R&D pact with Danish biotech Gubra ApS focused on obesity. BI entered its first obes